Advocacy Group Urges FDA Clarity

A coalition of rare disease advocacy groups has formally requested the Trump administration to reinstate regulatory clarity concerning the U.S. Food and Drug Administration's Center for Biologics Evaluation and Research. This appeal comes at a critical juncture as the administration considers new leadership for the center. The groups emphasize the importance of clear and consistent regulations to ensure timely access to treatments and to foster innovation in the development of therapies for rare diseases. Restoring this clarity is seen as vital for patient well-being and scientific progress.